A number of stock research firms have changed their ratings and price targets for Celgene (NASDAQ: CELG) during the last seven days:

  • Celgene had its “outperform” rating reaffirmed by analysts at Cowen.
  • Celgene had its “neutral” rating reaffirmed by analysts at Credit Suisse. They now have a $75.00 price target on the stock.
  • Celgene had its price target raised by analysts at Bank of America from $76.00 to $88.00. They now have a “buy” rating on the stock.
  • Celgene had its price target raised by analysts at Jefferies Group to $91.00. They now have a “buy” rating on the stock.
  • Celgene had its “sector perform” rating reaffirmed by analysts at RBC Capital. They now have a $75.00 price target on the stock.
  • Celgene had its price target raised by analysts at Robert W. Baird from $78.00 to $92.00. They now have an “outperform” rating on the stock.
  • Celgene had its “overweight” rating reaffirmed by analysts at Barclays Capital. They now have a $87.00 price target on the stock.

Shares of Celgene opened at 77.36 on Thursday. Celgene has a one year low of $58.53 and a one year high of $81.24. The company has a market cap of $33.375 billion and a P/E ratio of 22.49.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.